The role of PARP1 in regulating AR function in prostate cancer and the potential synergy between PARPi and AR signaling inhibitor was tested in another phase II randomized, double-blind study comparing olaparib and abiraterone versus placebo and abiraterone in mCRPC [27]. This evidence concerns the gene AR and prostate carcinoma.